The change of urine L-FABP for patients with SGLT2 inhibitor with type 2 diabetes

The change of urine L-FABP for patients with SGLT2 inhibitor with type 2 diabetes - Urine L-FABP with SGLT2 inhibitor

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047695

Enrollment

120

Registered

2022-05-09

Start date

2022-05-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatients with type 2 diabetes for 1st April 2013 to 30th April 2020, and including follows: 1.those who was with multiple sampling of urine L-FABP 2.20 years old and more 3.those who was the administration of SGLT2 inhibitors 4.those who do not refuse to participate in this research

Exclusion criteria

Exclusion criteria: 1.those who had serious liver or kidney diseases. 2.those who was with diabetic ketosis, coma, or pre-coma. 3.those who had infection, peri-operation, operation, or trauma. 4.those who was with pregnancy 5.those who was judged inappropriate as participants.

Design outcomes

Primary

Measure	Time frame
The urine L-FABP change with SGLT2 inhibitors in type 2 diabetic patients.	—

Countries

Japan

Contacts

Public ContactKyu Yong Cho

Hokkaido University Hospital Institute of Health Science Innovation for Medical Care

kyuyong-cho@med.hokudai.ac.jp011-706-7061

Outcome results